Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | January 02, 2026 | January 07, 2026 |
| Cyteir Therapeutics, Inc.CYT · Entity 92707 | Director | February 09, 2024 | February 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 26,893 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 9,500 · Balance 26,893 F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2: Each RSU represents a contingent right to receive one ordinary share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02 | Direct | 19,000 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 19,000 · Balance 19,000 F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
Cyteir Therapeutics, Inc.
Report date February 09, 2024 · Filed February 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,129 |
Reported balance
After 2024-02-09 transaction · row 1
1 source rowRow 1 · 2024-02-09 · Exercise / conversion · Acquired 12,129 · Balance 12,129 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03 | Direct | 0 |
Reported balance
After 2024-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-09 · Exercise / conversion · Disposed 12,129 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001913319-26-000002 · form4-01062026_080116.xml · derivative · entry 2 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Ordinary Shares · 19,000 shares Expires 2036-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001913319-26-000002 · form4-01062026_080116.xml · nonDerivative · entry 1 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,893 F1 · shares: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 10,787 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000919 · form4-01062025_070108.xml · derivative · entry 2 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Ordinary Shares · 10,787 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 5,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000919 · form4-01062025_070108.xml · nonDerivative · entry 1 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,393 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:41 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001415889-24-004638 · form4-02212024_090213.xml · derivative · entry 2 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Ordinary Shares · 24,000 shares Expires 2034-02-20 F3 · derivative.exercise_date: This option shall vest in three equal annual installments on February 20, 2025, February 20, 2026 and February 20, 2027. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:41 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004638 · form4-02212024_090213.xml · nonDerivative · entry 1 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 F1 · kind: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in three equal annual installments on February 20, 2025, February 20, 2026 and February 20, 2027. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 16:01 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,129 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-24-003348 · doc4.xml · derivative · entry 2 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,129 shares Expires 2033-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 16:01 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | Exercise / conversionCommon Stock | 12,129 | $1.69 | $20,498.01 |
DisclosureSEC source: 0001209191-24-003348 · doc4.xml · nonDerivative · entry 1 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 16:46 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 12,129 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-007557 · doc4.xml · derivative · entry 1 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,129 Underlying: Common Stock · 12,129 shares Expires 2033-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 16:53 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 28,300 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0000899243-22-007628 · doc4.xml · derivative · entry 1 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,300 Underlying: Common Stock · 28,300 shares Expires 2032-02-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of February 22, 2022, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.